- Indonesia
Implementer: Interactive Research & Development
Site: Rumah Sakit Islam Hospital (Jakarta)
Patients treated with:
Bedaquiline | 70 |
---|---|
Delamanid | 2 |
Enrollment in the observational study is now complete.
Implementer: Interactive Research & Development
Site: Rumah Sakit Islam Hospital (Jakarta)
Patients treated with:
Bedaquiline | 70 |
---|---|
Delamanid | 2 |
Enrollment in the observational study is now complete.
Implementer: Interactive Research & Development
Site: Rumah Sakit Islam Hospital (Jakarta)
Indonesia is one of the 30 MDR-TB high burden countries worldwide, with estimated 11,000 new patients eligible for MDR-TB treatment every year. The national MDR-TB prevalence is estimated at 2.8% among new TB Cases and 16% among previously treated TB cases.
Following the results from the national prevalence survey in Indonesia, it is now estimated that there are over 1 million new TB cases per year in Indonesia, twice the previously estimated total. This has led to an upward revision of global totals compared to estimated previously published (WHO Global TB Report 2017).
By end of 2015 Programmatic management of drug-resistant TB (PMDT) services were established at 34 referral hospitals, 14 sub referral hospitals and 1055 treatment satellites in 34 provinces of Indonesia. Since the start of the program in 2009 (initially only at 2 sites) till the end of 2015, there have been more than 4,500 patients enrolled in MDR-TB treatment.